U.S. spending on GLP-1 receptor agonists reached $71.7 billion in 2023. Semaglutide and tirzepatide products have captured 70% of the market as diabetes and weight loss medication use rapidly expands, according to new research.
March’s FDA approvals feature new biosimilars, first-in-class therapies, expanded indications, and diagnostic innovations across allergy, cardiology, gastroenterology, infectious diseases, and more.
Researchers highlight evidence-based lifestyle and pharmacologic strategies, including glycemic excursion minimization and tirzepatide, for early glycemic control in adults with type 2 diabetes.
Conexiant
Daily News
Stay up to date with the latest clinical headlines and other information tailored to your specialty.
Thank you for signing up for the Daily News alerts. You will begin receiving them shortly.
At 12 months, women on hormone therapy achieved 16% total body weight loss with semaglutide, compared to 12% in those not using hormone therapy, researchers reported.
"Given the global obesity epidemic and the widespread use of antidepressants, weight management and metabolic monitoring should be encouraged and integrated into depression follow-up guidelines alongside antidepressant prescriptions," the researchers concluded.